+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases



Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases



Archives of Neurology 56(6): 661-663



Administration of high-dose intravenous immunoglobulins has become one of the most successful new treatment regimens for demyelinating diseases. In a decade of molecular medicine, it came as a surprise that a natural blood product would prove effective in several disorders, including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and, probably, multiple sclerosis. Many experimental studies, both in vivo and in vitro, have shown that intravenous immunoglobulins can interfere with the immune system at several levels. In addition, intravenous immunoglobulins may promote remyelination in demyelinating disease associated with viral infections. At present, no single mode of action has been identified as the crucial mechanism, which leads us to suggest that multiple effects may act in concert.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010968179

Download citation: RISBibTeXText

PMID: 10369303

DOI: 10.1001/archneur.56.6.661


Related references

Combination of high-dose intravenous immunoglobulins and itraconozole in treating chronic mycotic demyelinating optic neuritis. Thescientificworldjournal 3: 640-646, 2003

Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins. Springer Seminars in Immunopathology 23(4): 447-457, 2001

Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System 11(4): 325-329, 2006

New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. Therapeutic Advances in Neurological Disorders 1(2): 52-61, 2008

Immunotherapy of high dose intravenous immunoglobulins: basic mechanisms of action and clinical implications. Polskie Archiwum Medycyny Wewnetrznej 106(5): 1071-1077, 2001

High dose intravenous immunoglobulins in therapeutic arsenal in autoimmune and systemic diseases. Therapie 48(2): 97, 1993

High-dose intravenous immunoglobulins in the treatment of immune blood cytopenia. Mechanisms of action, indications and results. Annales de Medecine Interne 141(8): 689-697, 1990

High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. Journal of the American Academy of Dermatology 56(6): 960-967, 2007

Treatment of connective tissue diseases with high dose intravenous immunoglobulins preliminary experiences in five cases. Recenti Progressi in Medicina 82(11): 603-605, 1991

High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. Journal of the American Academy of Dermatology 44(6): 1010-1024, 2001

Plasmapheresis and high-dose immunoglobulins in the treatment of acute demyelinating polyneuropathy. Minerva Anestesiologica 59(6): 307-311, 1993

High-dose intravenous immunoglobulins. Journal of Perinatal Medicine 24(5): 539, 1996

High dose intravenous immunoglobulin for chronic inflammatory demyelinating polyneuropathy. Archives of Physical Medicine & Rehabilitation 73(10): 1001, 1992

High-dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy. Italian Journal of Neurological Sciences 8(4): 321-326, 1987

Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases. Annales de Medecine Interne 144(8): 506-513, 1993